Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: kondo m. Eur Respir J. 2022 Dec 15;60(6):2200380. doi: 10.1183/13993003.00380-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35361630 Clinical Trial.
Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404.
Nishiyama O, Taniguchi H, Kondoh Y, Takada K, Baba K, Saito H, Sugino Y, Yamamoto M, Ogasawara T, Kondo M, Imaizumi K, Hasegawa Y, Suzuki R, Shimokata K; Central Japan Lung Study Group. Nishiyama O, et al. Among authors: kondo m. Anticancer Drugs. 2011 Sep;22(8):811-6. doi: 10.1097/CAD.0b013e3283440231. Anticancer Drugs. 2011. PMID: 21317767 Clinical Trial.
Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System.
Morise M, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E, Hase T, Ando M, Kondo M, Saito H, Hasegawa Y. Morise M, et al. Among authors: kondo m. Mol Clin Oncol. 2014 Nov;2(6):991-996. doi: 10.3892/mco.2014.354. Epub 2014 Jul 22. Mol Clin Oncol. 2014. PMID: 25279187 Free PMC article.
Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?
Kato T, Morise M, Ando M, Kojima E, Ogasawara T, Suzuki R, Shindoh J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Hase T, Kondo M, Saito H, Hasegawa Y. Kato T, et al. Among authors: kondo m. J Cancer Res Clin Oncol. 2016 Jul;142(7):1629-40. doi: 10.1007/s00432-016-2170-z. Epub 2016 May 11. J Cancer Res Clin Oncol. 2016. PMID: 27166967
Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Yoneshima Y, Morita S, Ando M, Miura S, Yoshioka H, Abe T, Kato T, Kondo M, Hosomi Y, Hotta K, Yamamoto N, Kishimoto J, Nakanishi Y, Okamoto I. Yoneshima Y, et al. Among authors: kondo m. Clin Lung Cancer. 2017 Jan;18(1):100-103. doi: 10.1016/j.cllc.2016.08.003. Epub 2016 Oct 3. Clin Lung Cancer. 2017. PMID: 28341108 Clinical Trial.
4,371 results